Navigation Links
WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
Date:12/11/2007

The company's leading market position -- a combination of national scale and local depth -- is expected to continue to generate strong growth and

enhanced value for members.

INDIANAPOLIS, Dec. 11 /PRNewswire-FirstCall/ -- WellPoint, Inc. (NYSE: WLP) today hosted its 2007 investor conference in Westlake Village, California. During the meeting, WellPoint's executive leadership team reviewed the company's performance over the past year and offered detailed company guidance for 2008.

"Our accomplishments during 2007 reflect the superior value proposition WellPoint brings to the marketplace. During the year, WellPoint continued to deliver strong enrollment growth and expanded the services and value we offer to our members," said Angela F. Braly, president and chief executive officer of WellPoint. "WellPoint also is improving our operational efficiency and reducing administrative costs as a percentage of revenue, while making strategic investments to grow our business in the future and provide superior service to our members."

Some of the milestones WellPoint achieved in 2007 included:

- Adding 704,000 members through the first nine months of the year,

including providing policies to an estimated 280,000 members who

previously had no health insurance.

- Rolling out industry-leading consumer driven health plans to all

customer segments.

- Successfully completing several system migrations, resulting in lower

technology production costs and improved information management

capabilities.

- Improving the selling, general and administrative expense ratio by 100

basis points during the first nine months of the year compared to the

first nine months of 2006.

- Introducing an Action Plan for the Uninsured, a comprehensive plan to

help reduce the growing ranks of the uninsured through a blend of

public a
'/>"/>

SOURCE WellPoint, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. WellPoint Announces Appearances at Upcoming Conferences
2. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
3. WellPoint Announces Realignment of Core Businesses; Names New Executives
4. Wellpoint NextRx Receives TIPPS Certification from the HR Policy Association
5. WellPoint NextRx Receives National Leadership Award for Innovative Web Tool
6. WellPoint Reports Third Quarter 2007 Results
7. WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors
8. WellPoint Provides Support and Resources to Most Vulnerable California Residents
9. WellPoint Announces Appointment of John Cannon III as Executive Vice President & General Counsel
10. Stanford study highlights cost-effective method of lowering heart disease risks
11. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 1The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 2The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 1Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 2Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 4Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 5AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4